Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$13.65 - $21.8 $327 - $523
-24 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$22.15 - $31.89 $66 - $95
-3 Reduced 11.11%
24 $1,000
Q4 2017

Feb 14, 2018

BUY
$24.23 - $30.93 $654 - $835
27
27 $1,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Capital Bank & Trust CO Portfolio

Follow Capital Bank & Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Bank & Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Capital Bank & Trust CO with notifications on news.